WO2020111524A8 - Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof - Google Patents

Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof Download PDF

Info

Publication number
WO2020111524A8
WO2020111524A8 PCT/KR2019/014164 KR2019014164W WO2020111524A8 WO 2020111524 A8 WO2020111524 A8 WO 2020111524A8 KR 2019014164 W KR2019014164 W KR 2019014164W WO 2020111524 A8 WO2020111524 A8 WO 2020111524A8
Authority
WO
WIPO (PCT)
Prior art keywords
salt
crystalline form
pharmaceutical use
compound
trifluoromethyl
Prior art date
Application number
PCT/KR2019/014164
Other languages
French (fr)
Korean (ko)
Other versions
WO2020111524A1 (en
Inventor
이민희
김선미
김훈택
Original Assignee
주식회사 티움바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 티움바이오 filed Critical 주식회사 티움바이오
Priority to JP2021530802A priority Critical patent/JP2022510928A/en
Priority to ES19889945T priority patent/ES2952033T3/en
Priority to US17/296,836 priority patent/US20220002312A1/en
Priority to EP19889945.2A priority patent/EP3889157B1/en
Priority to CN201980078178.9A priority patent/CN113166172A/en
Priority to CA3124684A priority patent/CA3124684A1/en
Publication of WO2020111524A1 publication Critical patent/WO2020111524A1/en
Publication of WO2020111524A8 publication Critical patent/WO2020111524A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Salts and crystalline forms of the compound of chemical formula 1, that is, (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidine]-3(2H,4H,7H)-yl)-1-phenylethyl)amino)butanoic acid according to the present invention are excellent in terms of general physicochemical properties, e.g., hygroscopicity, related substances, chemical stability, etc. and as such, can be utilized for pharmaceutical uses, such as the preparation of a pharmaceutical composition comprising same as an active ingredient.
PCT/KR2019/014164 2018-11-30 2019-10-25 Salt and crystalline form of puropyrimidine compound and pharmaceutical use thereof WO2020111524A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2021530802A JP2022510928A (en) 2018-11-30 2019-10-25 Salts and crystalline forms of flopyrimidine compounds and their pharmaceutical uses
ES19889945T ES2952033T3 (en) 2018-11-30 2019-10-25 Salt and crystalline form of a furopyrimidine compound and pharmaceutical use of these
US17/296,836 US20220002312A1 (en) 2018-11-30 2019-10-25 Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof
EP19889945.2A EP3889157B1 (en) 2018-11-30 2019-10-25 Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof
CN201980078178.9A CN113166172A (en) 2018-11-30 2019-10-25 Salt and crystal form of puropyrimidine compound and pharmaceutical use thereof
CA3124684A CA3124684A1 (en) 2018-11-30 2019-10-25 Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180151990A KR101973074B1 (en) 2018-11-30 2018-11-30 Salts and crystalline form of furopyrimidine compound, and pharmaceutical composition comprising same
KR10-2018-0151990 2018-11-30

Publications (2)

Publication Number Publication Date
WO2020111524A1 WO2020111524A1 (en) 2020-06-04
WO2020111524A8 true WO2020111524A8 (en) 2021-07-22

Family

ID=66281116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/014164 WO2020111524A1 (en) 2018-11-30 2019-10-25 Salt and crystalline form of puropyrimidine compound and pharmaceutical use thereof

Country Status (8)

Country Link
US (1) US20220002312A1 (en)
EP (1) EP3889157B1 (en)
JP (1) JP2022510928A (en)
KR (1) KR101973074B1 (en)
CN (1) CN113166172A (en)
CA (1) CA3124684A1 (en)
ES (1) ES2952033T3 (en)
WO (1) WO2020111524A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
WO2001029044A1 (en) * 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US9034850B2 (en) * 2009-11-20 2015-05-19 Sk Chemicals Co., Ltd. Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same
BR112014021331B1 (en) * 2012-02-28 2020-12-15 Tiumbio Co., Ltd GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND USE OF THESE
FR3037959B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Also Published As

Publication number Publication date
EP3889157A4 (en) 2022-08-31
CN113166172A (en) 2021-07-23
EP3889157B1 (en) 2023-07-26
EP3889157A1 (en) 2021-10-06
KR101973074B1 (en) 2019-04-26
CA3124684A1 (en) 2020-06-04
US20220002312A1 (en) 2022-01-06
JP2022510928A (en) 2022-01-28
WO2020111524A1 (en) 2020-06-04
EP3889157C0 (en) 2023-07-26
ES2952033T3 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
CA2397450A1 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
FR21C1010I2 (en) 2,4,DI-(HETERO-)ARYLAMINO(-OXY)-5 SUBSTITUTED PYRIMIDINES USED AS ANTINEOPLASTIC AGENTS
AU2003215753A1 (en) Imidazopyridine derivatives as kinase inhibitors
HRP20161657T1 (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
RU2435760C2 (en) 1n-quinazoline-2,4-diones
ME01312B (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2004087677A3 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
NZ612041A (en) Compounds and their use as bace inhibitors
WO2004000318A3 (en) Certain amino-substituted monocycles as kinase modulators
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
NZ588830A (en) Inhibitors of protein kinases
CA2344290A1 (en) Quinazoline derivatives
JP2012501312A5 (en)
HRP20060286T3 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2007020411A8 (en) Amide derivatives
WO2007050510A3 (en) Hiv integrase inhibitors
JP2007501210A5 (en)
MX2009007040A (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension.
WO2020111524A8 (en) Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof
WO2002000166A3 (en) New compounds useful as antibacterial agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19889945

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3124684

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021530802

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019889945

Country of ref document: EP

Effective date: 20210630